VEGFA and neoplasm: For the first time monacolin X has been studied in in vivo, ex vivo, in vitro and in silico models for explaining its action and mechanism as a potent inhibitor of angiogenesis and tumor angiogenesis acting via downregulating the VEGFR2 pathway upon VEGF stimulation.